tbuckley/cabot-search huggingface dataset:
Concurrent chemotherapy plus radiation therapy (CRT) in elderly patients (E): A retrospective analysis.
Authors: S. Patel, P. B. Wolff, B. Lin, A. B. Karnad
Journal: Journal of Clinical Oncology (2010)

e19660 Background: CRT is ideal treatment for many early stage or locally advanced cancers (ca). Few E (age ≥70 years) have been enrolled on clinical trials of CRT and there are no prospective data from trials designed for this group. Retrospective data on a cohort of E treated with CRT could be used to design prospective trials. Methods: We performed a retrospective analysis of all E treated with CRT as standard of care for any solid tumor at our institution 2002-08 (E treated with hormonal therapy plus RT, or treated sequentially were excluded). Primary endpoints were treatment completion rates without breaks, and change in ECOG performance status (PS) at the end of CRT. Secondary endpoints were outcomes and co-morbidity analyses. Comprehensive Geriatric Assessment (CGA) was not performed prior to CRT. Results: Data on 63 E treated with CRT were reviewed. Mean age 76 yrs (range 70-87 yrs; SD 4.69). 54 were male and 9 were female. 22 % had lung ca, 16 % head and neck ca, 40 %GI ca; 14 % other ca. 35 of 63 E (56 %) completed planned CRT without breaks; 6 of 63 E (10 %) had unplanned breaks during CRT. 75 % were ECOG 0-1, and 25 % were ECOG 2-3 at the start of CRT. At the end of CRT, 54 % were 0-1, and 46 % were ECOG 2-4. There were no deaths due to CRT. 38/63 E (60%) had 3 or > co-morbidities. Outcomes data was available for 76%: 19% CR; 8% PR; 30 % SD; 19 % PD; 25/63 E (40%) are alive and being followed. Conclusions: Although 56% of E completed CRT without breaks there was significant decline in PS at the end of CRT. CGA before, during and after CRT is essential in prospective trials testing CRT in this population to improve completion rates with better outcomes. No significant financial relationships to disclose.
Impact of art therapy (AT) on fatigue and quality of life (QoL) during adjuvant external beam irradiation (EBI) in breast cancer patients (pts): a randomized trial
Authors: F. Joly, D. Pasquier, C. Hanzen, N. Heutte, C. Levy, F. Le Tinier, M. Mousseau, C. Ciais, C. Murariu, M.-C. D'almeida, V. Szymczak, C. Leon, S. Darbas, M.-P. Rousselot, S. Mineur, C. Rieux, A. Leconte, O. Rigal, B. Clarisse, D. Allouache
Journal: Annals of Oncology (2016)
Evaluation of Extrinsic and Intrinsic Cues Involved in BCR-ABL-Induced Leukemogenesis
Authors: Pallavi Suhas Sontakke, Richard W.J. Groen, Katarzyna Koczula, Jennifer Jaques, Huipin Yuan, Ulrich Günther, Anton C. Martens, Edo Vellenga, Jan J. Schuringa
Journal: Blood (2014)
Immune Dysregulation after Hematopoietic Stem Cell Transplantation for Autoimmune Diseases Leading to Development of a Second Autoimmune Disorder: Role of Conditioning Regimen Used?.
Authors: Yvonne Loh, Yu Oyama, Laisvyde Statkute, Kathleen Quigley, Kimberly Yaung, Walter Barr, Richard K. Burt
Journal: Blood (2006)
Platelet Protease Nexin-1, a Serpin That Strongly Influences Fibrinolysis and Thrombolysis
Authors: Yacine Boulaftali, Benoit Ho-Tin-Noe, Ana Pena, Stéphane Loyau, Laurence Venisse, Benjamin Richard, Véronique Arocas, Jean-Philippe Collet, Martine Jandrot-Perrus, Marie-Christine Bouton
Journal: Blood (2010)
Allogeneic Hematopoietic Stem Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) Not in First Remission
Authors: Kendra L Sweet, Jeffrey E Lancet, Ryan Hillgruber, Megan Melody, Amina Llishi, Janelle Perkins, Hugo F. Fernandez, Teresa Field
Journal: Blood (2015)
5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer
Authors: M. Roberto, A. Romiti, A. Botticelli, F.R. Di Pietro, L. Lionetto, G. Gentile, F. Mazzuca, R. Falcone, M. Occhipinti, S. Macrini, E. Anselmi, A. Petremolo, C.E. Onesti, M. Simmaco, P. Marchetti
Journal: Annals of Oncology (2016)
Sequential Treatment with Chemotherapy and Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Fanconi Anemia Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Authors: Alexis Talbot, Regis Peffault de Latour, Nimrod Buchbinder, Reza Tabrizi, Etienne Lengliné, Stephane Vigouroux, Noel Milpied, Mauricette Michallet, Gerard Socie
Journal: Blood (2012)
The Safety of Hematopoietic Stem Cell Harvest from Elderly Family Donor in Japan
Authors: Tsutomu Takahashi, Ritsuro Suzuki, Hiroyasu Ogawa, Takahiro Fukuda, Kazuteru Ohashi, Shuichi Taniguchi, Yoshinobu Kanda, Hiromasa Abe, Yoshihisa Kodera, Junji Suzumiya
Journal: Blood (2015)
Occurrence and Treatment of Isolated Extramedullary Relapses after Allogeneic Hematopoietic Stem Cell Transplantation for Leukaemias: A Single Institute Experience with 442 Patients.
Authors: Dariusz Kata, Jerzy Holowiecki, Jerzy Wojnar, Beata Stella-Holowiecka, Slawomira Krzemien, Krzysztof Wozniczka, Grzegorz Helbig
Journal: Blood (2006)
RARE-36. PLEOMORPHIC XANTHOASTROCYTOMA WITH ANAPLASTIC FEATURES: A CASE REPORT
Authors: Muhammad Iqbal, Scott Turner
Journal: Neuro-Oncology (2016)

Pleomorphic xanthoastrocytoma (PXA) is a rare WHO Grade II neoplasm that often presents with seizures in children and young adults and has a supratentorial, typically temporal, predilection. The latest WHO classification includes a rare subtype with anaplastic features. These tumors demonstrate high mitotic activity of > 5 mitosis per 10 high powered field, focal positivity of CD-34, synaptophysin, MIB-1 labeling index, and P53 reactivity. Histologically, they exhibit spindle cells admixed with multinucleated giant cells showing lipidized vacuolated cytoplasm, intranuclear cytoplasmic inclusion, and eosinophilic granular bodies. Focal areas of necrosis are often seen. They are thought to arise from a malignant transformation of lower grade PXA, and the underlying molecular events behind this are not understood, though BRAF may play a role. Prognosis is significantly poorer than in the lower grade variants. There have been fewer than 11 cases reported in literature and thus a consensus on optimal treatment has not been reached. Herein, we present a case of PXA with anaplastic features in a 37 year-old woman and discuss her clinical course along with treatment, which included Temozolomide, Bevacizumab, and Optune Tumor Treating Fields.
Direct Interaction With Bone Marrow Mesenchymal Stromal/Stem Cells Is Required For Hematopoietic Expansion By Parathyroid Hormone
Authors: Hisayuki Yao, Yasuo Miura, Satoshi Yoshioka, Masaki Iwasa, Atsushi Sato, Akihiro Tamura, Asumi Yokota, Eishi Ashihara, Tatsuo Ichinohe, Hideyo Hirai, Taira Maekawa
Journal: Blood (2013)
Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.
Authors: Dapeng Wang, Yu Yu, Kenrick M Semple, Kelley M.K. Haarberg, Jianing Fu, Kane Kaosaard, Claudio Anasetti, Nagaraj Srinivas, Dmitry Gabrilovich, Xue-Zhong Yu
Journal: Blood (2012)
Phase II study of docetaxel (DTX) and S-1 as neoadjuvant chemotherapy for potentially R0 advanced gastric cancer.
Authors: Yasunori Emi, Eiji Oki, Hiroshi Saeki, Masaru Morita, Tetsuya Kusumoto, Hiroshi Matsuura, Mototsugu Shimokawa, Yoshihiro Kakeji, Hideo Baba, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2013)

74 Background: This trial sought to evaluate the efficacy and safety of preoperative chemotherapy with DTX plus S-1 for advanced gastric cancer with poor prognosis even after R0 curative resection. We show the 2 years follow-up data. Methods: Preoperative staging was confirmed by laparoscopy. Eligibility criteria included 1) negative peritoneal cytology, H0, P0 and M0, 2) possible curative resection, and 3) ECOG PS 0-1. Patients received DTX (35 mg/m 2 ) on days 1 and 15, and daily oral administration of S-1 (80 mg/m 2 /day) for days 1–14 every 4 weeks of 2 courses, followed by gastrectomy with D2 lymphadenectomy. The primary endpoint was pathological response rate (pRR). A sample size of 45 was planned for the expected pRR of 40% and threshold value of 20%, with one-sided alpha of 0.05 and beta of approximately 0.1. Results: A total of 47 patients were centrally registered between November 2007 and November 2009 from 14 centers. All patients were eligible for analysis. The median age was 63 (range 37–79); male/female: 36/11; PS0/1:41/6; and clinical stage IIIA/IIIB: 31/16. The target pRR was 47% (90%CI, 34–60%; p&lt;0.0001). Forty six patients (98%) underwent surgery, in whom curative resection was performed in 44 patients, and 37 patients completed the protocol treatment. The response to preoperative chemotherapy was PR/SD/PD/NE in 16/24/2/5 with a response rate of 34%. The rate of 2 years and 3 years DFS were 53.9%, and 49.3%, respectively. The rate of 2 years and 3 years Overall survival were 69.6%, and 55.1%, respectively. The most common toxicities of neoadjuvant chemotherapy were grade 3/4 neutropenia (42%), febrile neutropenia (4%), grade 2 anorexia (21%), and fatigue (15%). Major operative morbidity included pancreatic fistula (9%), abdominal abscess (11%), pneumonia (2%), and anastomotic leakage (0%). No patients died due to surgical complications. Conclusions: The combination of DTX and S-1 was well tolerated and promising as a preoperative chemotherapy regimen for patients with potentially resectable advanced gastric cancer. Clinical trial information: UMIN000000875.
RTHP-09. PROGRESSION AND PSEUDOPROGRESSION OF GLIOBLASTOMA MULTIFORME IN THE TEMOZOLOMIDE ERA
Authors: Lindsay Rowe, John Butman, Megan Mackey, Joanna Shih, Mary Hawes, Theresa Cooley Zgela, Holly Ning, DeeDee Smart, Mark Gilbert, Kevin Camphausen, Andra Krauze
Journal: Neuro-Oncology (2016)

Standard of care for glioblastoma(GBM) includes temozolomide with radiotherapy. Pseudoprogression has been documented with increased frequency, complicating assessment of early imaging studies after chemoradiation (CRT). MATERIALS: Of 114 consecutive patients receiving CRT for newly diagnosed GBM at our institute between 1998 and 2015, 85 had pre and post-treatment charts and imaging suitable for retrospective evaluation using currently accepted RANO criteria. Patient status was classified at 3 months from baseline post-radiation imaging as, partial response/stable disease(PR/SD), pseudoprogression(PsP), and true progression(TP). At the three-month time point there were 37(43.5%) with PR/SD, 16(18.8%) PsP, and 23(27.0%) TP. Nine(10.7%) patients were not evaluable due to early initiation of bevacizumab. Age and sex were equally distributed between groups. Trends toward increased rates of gross total resection in PR/SD, and periventricular location for TP, were seen. Rates of MGMT methylation were 50%(PR/SD), 55.6%(PsP), and 16.7%(TP). Early imaging one month after the post-radiation baseline demonstrated increased contrast enhancement in all PsP cases (none had stabilized or improved), 93.7% had increased tumor perfusion (relative cerebral blood volume), and 50% had increased FLAIR signal. No differences were noted in mean tumor volumes, or location of pseudoprogression in reference to radiation isodose levels. Most importantly, for PR/SD, PsP, and TP, median PFS was 9.80, 9.07, and 4.16 months (p ˂ 0.0001) and median OS was 27.0, 20.7, and 14.0 months(p = 0.0042), respectively. Contrary to published reports, our data do not demonstrate an improvement in survival outcomes for patients with pseudoprogression compared to stable disease or response on first post-radiation imaging. Our data may be limited by patient numbers but importantly, there were no early imaging characteristics, including perfusion imaging, that differentiated pseudoprogression from true progression. These results underscore the need for continued investigations to develop non-invasive techniques to predict pseudoprogression and accurately predict overall survival.
Efficacy and safety of nivolumab in elderly patients (pts) with advanced squamous non small cell lung cancer (Sq-NSCLC) participating in the expanded access programme (EAP) in Italy
Authors: F. Grossi, L. Crinò, A. Misino, P. Bidoli, A. Delmonte, F. Gelsomino, C. Proto, M. Mancini, L. Landi, D. Turci, S. Quadrini, P. Antonelli, P. Marchetti, L. Toschi, S. Giusti, F. Di Costanzo, F. Rastelli, P. Sandri, V. Scotti, F. de Marinis
Journal: Annals of Oncology (2016)
Good news for French NSCLC patients: Distance between chest and surgical departments did not impair outcome
Authors: D. Debieuvre, B. Asselain, M.L. Braud, C. Fouret, S. Larive, L. Falchero, Y. Duval, B. Lemaire, M. Farny, P. Brun, C. Dujon, C. Nocent, P. Dumont, P. Le Lann, G.-J. Kassem, M. Grivaux
Journal: Annals of Oncology (2016)
How to reduce the risk of recurrence after surgical treatment of colorectal liver metastases?
Authors: L. Benhaim, D. Goárá, S. Bonnet, F. Dumont, D. Malka, M. Ducreux, C. Eveno, D. Elias
Journal: Journal of Clinical Oncology (2011)

544 Background: After surgery with curative intent for colorectal liver metastases (MHCCR), liver recurrence occurs in more than 60% of patients, despite the administration of adjuvant systemic chemotherapy. The objective of this study was to compare the prognosis of patients operated on MHCCR with high risk of recurrences in the liver, treated by postoperative chemotherapy hepatic arterial infusion (HAI) by oxaliplatin, to that obtained after adjuvant systemic chemotherapy. Methods: From January 2000 to December 2009, 113 patients who underwent curative resection of more than 3 MHCCR, were selected from a prospective database. Among these 113 patients, 47 had received postoperative HAI associated with systemic chemotherapy (HAI+) and 66, systemic chemotherapy alone (HAI-). Results: The two groups were comparable in age, sex, stage of primary, rates of synchronous (&gt; 75%), and bilobar (&gt; 90%) MHCCR. The number of MHCCR was significantly higher in the group HAI+ (p &lt; 0.0001). Twenty-seven patients (57%) received more than 6 courses of HAI. HAI was discontinued in 6 patients (12%) due to technical problems with the catheter. After a median follow up of 75 months (7-125), the overall survival and recurrence-free survival at 5 years were higher for patients HAI+ compared to those HAI-, respectively 52.9% vs. 12.3% (p = 0.06) and 30.8% vs. 2% (p &lt; 0.0001). Conclusions: The postoperative administration of oxaliplatin-based HAI associated to systemic chemotherapy after cure of MHCCR, improves recurrence-free survival of patients at high risk of hepatic recurrence, compared to systemic chemotherapy alone. No significant financial relationships to disclose.
Chemoresistance to Prednisolone as Treatment Stratification Criteria In the Adult ALL Therapeutic Approach of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group
Authors: Elena N Parovichnikova, Galina A Kliasova, Valentin G Isaev, Andrey N Sokolov, Sergey M Kulikov, Tatyana S Kaporskaya, Olga Yu Baranova, Elena V Kondakova, Tatyana V Ryltzova, Julia R Davidyan, Valeri G Savchenko
Journal: Blood (2010)
Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry
Authors: Sebastian Birndt, Thomas Schenk, Frank M. Brunkhorst, Georg Maschmeyer, Frank Rothmann, Thomas Weber, Markus Müller, Jens P. Panse, Roland Schroers, Jan Braess, Norbert Frickhofen, Gritta Janka, Kai Lehmberg, Andreas Hochhaus, Thomas Ernst, Paul La Rosée
Journal: Blood (2016)
Prognostic impact of proliferation for resected early stage breast cancer according to histology: Cut-off analysis of Ki67 in 859 patients with pure invasive lobular and ductal breast carcinoma (ILC/IDC)
Authors: L. Carbognin, I. Sperduti, M.V. Dieci, I. Zampiva, G. Griguolo, S. Pilotto, V. Guarneri, M. Brunelli, R. Nortilli, E. Manfrin, E. Fiorio, V. Parolin, E. Filippi, F. Pellini, F. Bonetti, G.P. Pollini, P.F. Conte, G. Tortora, E. Bria
Journal: Annals of Oncology (2016)
A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients &amp;lt; 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.
Authors: Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson
Journal: Blood (2005)
Pelvic malignancies undergoing exenteration.
Authors: R. J. Chokshi, D. Arrese, M. P. Kuhrt, M. Routt, E. Kocak, E. W. Martin
Journal: Journal of Clinical Oncology (2011)

579 Background: Pelvic exenteration is reserved for patients with locally invasive and recurrent pelvic malignancies. The literature demonstrates a high morbidity and mortality associated with this operation. At our institution, a high volume of pelvic exenterations are undertaken and their outcomes have been studied. Methods: The medical records of 53 patients with varying pelvic pathologies who underwent pelvic exenteration between 2004 and 2010 were reviewed. Demographics, histologies, periprocedural events, and outcomes were analyzed. Results: Patients were divided into a colorectal (n = 37) and noncolorectal (n = 16) group for analysis based on histology. The two groups were similar in demographics, perioperative events, and length of stay. Resection status, chemotherapy use, and intraoperative radiation therapy showed no statistical difference. Complications showed a difference in perineal abscesses in the colorectal group. The colorectal group showed a survival difference when comparing R0 resection versus R1/R2, however no difference was seen in primary versus recurrent tumors. The median survival was 20.3 months in the colorectal group and 4.8 months in the noncolorectal group. Conclusions: Patients undergoing exenteration for colorectal histology have improved survival when compared to pelvic malignancies of other origins. The greatest effect on long term survival is seen in the colorectal group undergoing a R0 resection. Despite pelvic exenterations carrying a high morbidity and mortality, careful patient selection can optimize outcomes. [Table: see text] No significant financial relationships to disclose.
ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011)
Authors: Michael Vogelbaum, Andrew Lassman, Ian Lee, Linda Liau, Adam Sonabend, Tobias Walbert, Liqiang Yang, Asha Das, Timothy Cloughesy
Journal: Neuro-Oncology (2016)

Toca 511 (vocimagene amiretrorepvec), a live gamma retrovirus, encodes the transgene cytosine deaminase (CD). Toca 511 selectively infects, persists and spreads in actively proliferating cancer cells. Subsequent oral administration of the extended-release antifungal drug 5-fluorocytosine (Toca FC) results in production of 5-fluorouracil (5-FU), via the CD enzyme, within infected cells. 5-FU kills cancer cells and myeloid derived suppressor cells and activates the immune system against cancer, leading to durable antitumor immune responses in animal models. This sequence of events is amplified with multiple cycles of 5-fluorocytosine. Clinical data from 2 ongoing phase 1 trials (NCT01156584, NCT01470794) in recurrent high grade glioma (HGG) are consistent with this mechanism of action, and show a favorable safety profile and extended survival compared to historical controls. Standard of care for newly diagnosed HGG includes maximum safe extent resection and chemoradiation with temozolomide (TMZ). A Phase 1b study, treating newly diagnosed HGG subjects with Toca 511 and Toca FC added to standard of care (SOC), will examine safety and overall survival (OS) compared to historical controls. Based on the high unmet need for effective therapies and the additive preclinical efficacy demonstrated with Toca 511 and radiation or TMZ, this multi-center, open-label study will enroll approximately 24 subjects with newly diagnosed HGG prior to tissue diagnosis or definitive initial surgical resection. Subjects will be treated with Toca 511 and dose escalation of Toca FC added to SOC. The primary objective is to establish the recommended Phase 2 dose of Toca FC and secondary objectives are to evaluate the safety, tolerability and preliminary efficacy as measured by OS and progression-free survival. Evidence for immunologic mechanisms of disease control and molecular profiling of resected tumor samples will be evaluated to identify potential biomarkers for treatment-related response.
Targeting Angiogenesis in Cancer: Bevacizumab-Induced Platelet Activation as a Possible Cause for Unexpected Arterial Thromboembolic Events in Clinical Trials.
Authors: Todd Meyer, Theresa Robson, Ali Amirkhosravi, Florian Langer, Hina Desai, Mildred Amaya, Pierre Elias, John L. Francis
Journal: Blood (2006)
Hematologic outcomes of epoetin-alpha-treated cancer patients based on initial intervention of Hb &lt;10 compared to Hb 10–11 g/dL: Results from a prospective observational study
Authors: Q. Wang, E. Chen, K. Larholt, B. Bookhart, R. McKenzie, C. Tak Piech
Journal: Journal of Clinical Oncology (2007)

19542 Background: Current guidelines recommend consideration of epoetin alfa (EPO) therapy for chemotherapy-induced anemia (CIA) when Hb &lt;11 g/dL (National Comprehensive Cancer Network) or Hb &lt; 10g/dL (ASCO/ASH). To evaluate clinical outcomes in EPO-treated patients initiated at Hb &lt; 10 v. 10–11 g/dL, an analysis was conducted of clinical outcomes from practice settings. Data were analyzed from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (D.O.S.E.) Registry, an ongoing, prospective registry collecting data on real-world practice patterns. Methods: Data from 29 U.S. hospital and community-based outpatient practices were assessed from 1/04–10/06. Chemotherapy-treated adult patients with a non-myeloid malignancy, baseline anemia (Hb &lt; 11 g/dL), receipt of at least two EPO doses, and study completion were included. This analysis stratified patients based on Hb level at EPO initiation. Outcomes assessed included proportion of patients requiring RBC transfusion, mean treatment duration, and proportion of patients achieving an Hb = 11 g/dL. Results: 245 patients were eligible for analysis. 97 patients were initiated at a Hb &lt; 10 g/dL and 148 patients were initiated at Hb 10–11 g/dL Baseline characteristics (age, gender distribution, weight, platinum-based therapy, Karnofsky score, primary tumor type) were similar except baseline Hb (9.4 g/dL v. 10.5 g/dL). Treatment duration was similar in both groups at approximately nine weeks. Transfusion outcomes and time to NCCN target Hb level (Hb =11 g/dL) are described in the table . Conclusions: This ongoing observational study demonstrated over two-thirds of patients achieved NCCN target Hb = 11 g/dL. Additional benefits for the patients initiated at Hb 10–11 g/dL were a shorter time to NCCN target Hb and a lower proportion of patients requiring transfusions. These results support the use of EPO for patients with chemotherapy-induced anemia and Hb &lt; 11 g/dL. [Table: see text] No significant financial relationships to disclose.
GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens.
Authors: Elizabeth A. Gruber, Myron S. Czuczman, Scott H. Olejniczak, Joy Knight, Francisco J. Hernandez-Ilizaliturri
Journal: Blood (2007)
Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents with An Anthracycline Based Regimen, but without High Doses of Cytarabine and Methotrexate: Preliminary Results of the LAFAMI-LLA-2002 Protocol.
Authors: Gregorio Campos-Cabrera, Virgina Campos-Cabrera, Jose-Luis Campos-Villagomez
Journal: Blood (2009)
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
Authors: W. Xie, C. Sweeney, M. Regan, M. Nakabayashi, M. Buyse, N. Clarke, L. Collette, J. Dignam, K. Fizazi, M. Habibian, S. Halabi, P. Kantoff, W. Parulekar, H.M. Sandler, O. Sartor, H. Soule, M. Sydes, B. Tombal, S. Williams
Journal: Annals of Oncology (2016)